Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon beta-1a Nebuliser 48 μg/mL · 1 trial · 1 indication
Evaluation of the efficacy of inhaled AZD9412 compared to placebo in preventing severe exacerbations during the 14 day treatment phase following the onset of an URTI in asthmatic patients. A severe exacerbation was defined as worsening asthma symptoms and 1. use of systemic corticosteroids (or a temporary increase of at least 2-fold in a stable oral corticosteroid background dose) for at least 3 consecutive days and/or 2. an unscheduled visit or emergency room visit due to asthma symptoms that required at least 1 dose of systemic corticosteroids and/or 3. an in-patient hospitalisation due to asthma requiring at least 1 dose of systemic corticosteroids. The number of patients with severe asthma exacerbations with onset during the treatment phase is presented for each treatment group.
| Arm | Type | Description |
|---|---|---|
| Placebo (matching) | PLACEBO_COMPARATOR | Placebo, once daily inhalation for 14 days |
| Interferon beta-1a | EXPERIMENTAL | Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days |
| Name | Type | Description |
|---|---|---|
| Interferon beta-1a Nebuliser solution 48 μg/mL | DRUG | Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days |
| Placebo | DRUG | Placebo solution for once daily inhalation for 14 days |
Inclusion Criteria: For inclusion in the study patients should fulfil the following criteria: 1. Provision of signed and dated written informed consent prior to any study specific procedures 2. Male or female aged 18 and above at the time of enrolment 3. History of physician-diagnosed asthma requi...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Interferon beta-1a Nebuliser 48 μg/mL is an inhaled formulation being developed for the treatment of asthma. It is given once daily by nebuliser and was studied in adults with asthma after the onset of symptoms of an upper respiratory tract infection.
Interferon beta-1a Nebuliser 48 μg/mL is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating this inhaled interferon beta-1a formulation in asthma.
Interferon beta-1a Nebuliser 48 μg/mL is in Phase 2 development. It is an investigational product and has not been approved for marketing. The Phase 2 study of this formulation has been completed.
Interferon beta-1a Nebuliser 48 μg/mL was studied in the Phase 2 trial NCT02491684, titled A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection.
The Phase 2 trial NCT02491684 enrolled 121 adults with asthma. It was randomized, double blind, and placebo controlled, with participants receiving 14 days of once daily inhaled treatment. The study ran in Argentina, Australia, Colombia, France, South Korea, Spain, and the United Kingdom.